STAT Plus: Gilead loses its challenge to a pair of U.S. patents over an HIV prevention pill

In a setback to Gilead Sciences (GILD), a federal panel rejected its bid to invalidate a pair of patents owned by the U.S. government for using the Truvada pill to prevent HIV, a drug that has sparked controversy due to its cost and the extent to which taxpayer dollars funded crucial research.

The Patent Trial and Appeals Board ruled that Gilead failed to demonstrate it was likely to win its argument for overturning the patents held by the Centers for Disease Control and Prevention, which helped fund academic work into HIV prevention that later formed the basis for the best-selling medicine that is also known as PrEP (here is one ruling and here is the other).

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Gilead loses its challenge to a pair of U.S. patents over an HIV prevention pill »